Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: Systematic review and pooled analysis of randomized studies

Expert Opinion on Drug Safety

Volumn 11, Issue SUPPL. 1, 2012, Pages

  Petrelli, Fausto ^a   Borgonovo, Karen ^a   Cabiddu, Mary ^a   Ghilardi, Mara ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Epidermal growth factor receptor; Hypomagnesemia; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; INCIDENCE; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MEDLINE; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STANDARD; SYSTEMATIC REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MAGNESIUM; MAGNESIUM DEFICIENCY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK;

EID: 84858695125     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.606213     Document Type: Review

References (59)

1. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32s-40s (Pubitemid 32880077)
2. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7(Suppl 4):2-8 (Pubitemid 34977157)
3. Wells A. Molecules in focus: EGF receptor. Int J Biochem Cell Biol 1999;31:637-43
4. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99 (Pubitemid 46606324)
5. Erbitux package insert. March 2006. ImClone Systems Incorporated, New York, NY 10014, USA. and Bristol-Myers Squibb Co; Princeton, NY 08543, USA
6. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007;18:7-15 (Pubitemid 44949790)
7. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;22:5235-41
8. Vectibix (panitumumab) prescribing information. (v3, revOctober 2007) Amgen, Inc.: Thousand Oaks, CA. Available from: http://www.vectibix.com/pdfs/ misc/vectibix pi.pdf Accessed 10 March 2008
9. Groenestege WM, Thebault S, Van Der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007;117:2260-7 (Pubitemid 47219571)
10. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med 1997;127:531-7 (Pubitemid 27419445)
11. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcv20-30-992.pdf
12. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88 (Pubitemid 17189972)
14. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6 (Pubitemid 27465551)
15. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
16. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311-19
17. Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19(4):734-8 (Pubitemid 351461045)
18. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin corrected, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25(36):5777-84
19. Erratum in: J Clin Oncol 2008;26(19):3295
20. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357(20):2040-8 (Pubitemid 350106711)
21. Burtness B, Goldwasser MA, Flood W, et al. Eastern cooperative oncology group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-54 (Pubitemid 46211507)
22. Erratum in: J Clin Oncol 2006;24(4):724
23. Adams RA, Meade AM, Madi A, et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 2009;100(2):251-8
24. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28(6):911-17
25. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. abstract 4000. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Illinois
26. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. abstract 4035. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Illinois
27. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27(5):672-80
28. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64 (Pubitemid 46797944)
29. Siena S, Cassidy J, Tabernero J, et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. abstract 283. 2010 Gastrointestinal Cancers Symposium. January 22-24, 2010; Orlando, Florida
30. Peeters M, Price TJ, Hotko YS, et al. Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Patient-reported outcomes (PRO) abstract 282. 2010 Gastrointestinal Cancers Symposium. January 22-24, 2010; Orlando, Florida
31. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-4 (Pubitemid 41258228)
32. Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 2006;6:152-6 (Pubitemid 44445751)
33. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;8:387-94 (Pubitemid 46621761)
34. Daugaard G, Strandgaard S, Holstein-Rathlou N-H, et al. The renal handling of sodium and water is not affected by the standard-dose cisplatin treatment for testicular cancer. Scand J Clin Lab Invest 1987;47:455-9 (Pubitemid 17102126)
35. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;50:203-18 (Pubitemid 47095077)
36. Nakopoulou L, Stefanaki K, Boletis J, et al. Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol Dial Transplant 1994;9:764-9 (Pubitemid 24209755)
37. Groenestege WM, Thebault S, Van Der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007;117:2260-7 (Pubitemid 47219571)
38. Hunter RJ, Pace MB, Burns KA, et al. Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment. Support Care Cancer 2009;17(9):1195-201
39. Bodnar L, Wcislo G, Gasowska-Bodnar A, et al. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 2008;44(17):2608-14
40. Saif MW. Management of hypomagnesemia in cancer patients receiving chemotherapy. J Support Oncol 2008;6(5):243-8 (Pubitemid 351836614)
41. Hodgkinson E, Neville-Webbe HL, Coleman RE. Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) 2006;18(9):710-18 (Pubitemid 44464042)
42. Lofts FJ, Evans TR, Wastnage R, Mansi JL. Magnesium supplements with cisplatin chemotherapy. Eur J Cancer 1996;32A(3):556-7 (Pubitemid 126402135)
43. Evans TR, Harper CL, Beveridge IG, et al. A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 1995;31A(2):174-8
44. Martin M, Diaz-Rubio E, Casado A, et al. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 1992;15(4):348-51
45. Vokes EE, Mick R, Vogelzang NJ, et al. A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia. Br J Cancer 1990;62(6):1015-17
46. Kibirige MS, Morris-Jones PH, Addison GM. Prevention of cisplatin-induced hypomagnesemia. Pediatr Hematol Oncol 1988;5(1):1-6
47. Willox JC, McAllister EJ, Sangster G, Kaye SB. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 1986;54(1):19-23 (Pubitemid 16093180)
48. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90(6):929-31 (Pubitemid 9244593)
49. Sgambato A, Wolf FI, Faraglia B, Cittadini A. Magnesium depletion causes growth inhibition, reduced expression of cyclin D1 and increased expression of p27kip1 in normal but not in transformed mammary epithelial cells. J Cell Physiol 1999;180:245-54 (Pubitemid 29297201)
50. Wolf FI, Trapani V. Cell (Patho) physiology of Magnesium. Clin Sci 2008;114:27-35
51. Maier JAM, Nasulewicz-Goldeman A, Simonacci M, et al. Insights into the mechanisms involved in magnesium-dependent inhibition of primary tumor growth. Nutr Cancer 2007;59:192-8 (Pubitemid 350230737)
52. Maier JAM, Malpuech-Brugere C, Zimowska W, et al. Low magnesium promotes endothelial dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 2004;1689:13-24
53. Vincenzi B, Santini D, Galluzzo S, et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008;14:4219-24
54. Nasulewicz A, Wietrzyk J, Wolf FI, et al. Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice. Biochim Biophys Acta 2004;1739:26-32 (Pubitemid 39647707)
55. Mazur A, Maier JAM, Rock E, et al. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys 2007;458:48-56 (Pubitemid 46201802)
56. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49 (Pubitemid 351656458)
57. Bernardini D, Nasulewicz A, Mazur A, Maier JAM. Magnesium and microvascular endothelial cells: a role in inflammation and angiogenesis. Front Biosci 2005;10:1177-82
58. Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 2007;14:377-86
59. Vincenzi B, Galluzzo S, Santini D, et al. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 2011;22(5):1141-6